We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Ventas Gain from $1.5B Life-Sciences Real Estate Deal?
Read MoreHide Full Article
In a remarkable development, Ventas Inc. (VTR - Free Report) signed a deal to acquire significantly all of the life science and medical real estate assets of Wexford Science & Technology, LLC. from Blackstone Group LP (BX - Free Report) for $1.5 billion in cash. The transaction is expected to close in fourth-quarter 2016, subject to closing norms.
The move marks the company’s foray into the thriving university-affiliated life science real estate business and is expected to be accretive to Ventas’s normalized funds from operations (“FFO”) in 2017 by 7–9 cents per share on a leverage-neutral basis.
Notably, Wexford, a leading university focused developer, had been a part of BioMed Realty Trust Inc. – a company that Blackstone had purchased in January this year.
The portfolio involves 23 operating properties with 4.1 million square feet and two development assets comprising around 400,000 square feet of space. The company is also buying nine development sites mainly adjacent to existing assets.
Tenants of these assets comprise leading universities, academic medical centers and research companies, including Yale University, the University of Pennsylvania Health System, Washington University in St. Louis, Wake Forest University and Alexion Pharmaceuticals, Inc.
As part of the buyout, Ventas will enter into an agreement that would allow the company exclusive rights to jointly develop future projects with Wexford. On the other hand, Wexford will continue to manage the portfolio and be independently owned and operated.
Moreover, total consideration for the deal is $1.5 billion, together with the assumption of $33 million of liabilities. Notably, Ventas would sell up to 10.35 million shares and use the proceeds to finance the transaction.
The Benefit
The deal is a strategic fit given the scope to capitalize on the increasing health-care-driven research and development driven by top-tier research universities. Increasing longevity of the aging U.S. population coupled with biopharma drug development growth opportunities are fueling the institutional life science and medical-market fundamentals. Moreover, long lease terms and top rated, institutional quality tenants assure steady growth in cash flows for Ventas.
Further, addition of 100% private pay assets would increase Ventas’s net operating income (NOI) contribution from private pay assets to 84%, which is encouraging. In fact, pro forma for the Wexford transaction, the assets acquired would reap around 5% of Ventas’s total NOI.
In Conclusion
Ventas’ large and diversified healthcare portfolio will help it benefit from an increasing healthcare spending, aging population and a rise in insured individuals. Further, the above-mentioned acquisition deal is consistent with the company’s strategy of adding high-quality properties generating improving cash flows. Yet, stiff competition keeps us concerned.
Ventas currently has a Zacks Rank #3 (Hold). Investors interested in the REIT industry can also consider stocks like other better-ranked stocks like HCP Inc. (HCP - Free Report) and Omega Healthcare Investors Inc. (OHI - Free Report) . Both the stocks has a Zacks Rank #2 (Buy)..
Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will Ventas Gain from $1.5B Life-Sciences Real Estate Deal?
In a remarkable development, Ventas Inc. (VTR - Free Report) signed a deal to acquire significantly all of the life science and medical real estate assets of Wexford Science & Technology, LLC. from Blackstone Group LP (BX - Free Report) for $1.5 billion in cash. The transaction is expected to close in fourth-quarter 2016, subject to closing norms.
The move marks the company’s foray into the thriving university-affiliated life science real estate business and is expected to be accretive to Ventas’s normalized funds from operations (“FFO”) in 2017 by 7–9 cents per share on a leverage-neutral basis.
Notably, Wexford, a leading university focused developer, had been a part of BioMed Realty Trust Inc. – a company that Blackstone had purchased in January this year.
VENTAS INC Price
VENTAS INC Price | VENTAS INC Quote
The Deal
The portfolio involves 23 operating properties with 4.1 million square feet and two development assets comprising around 400,000 square feet of space. The company is also buying nine development sites mainly adjacent to existing assets.
Tenants of these assets comprise leading universities, academic medical centers and research companies, including Yale University, the University of Pennsylvania Health System, Washington University in St. Louis, Wake Forest University and Alexion Pharmaceuticals, Inc.
As part of the buyout, Ventas will enter into an agreement that would allow the company exclusive rights to jointly develop future projects with Wexford. On the other hand, Wexford will continue to manage the portfolio and be independently owned and operated.
Moreover, total consideration for the deal is $1.5 billion, together with the assumption of $33 million of liabilities. Notably, Ventas would sell up to 10.35 million shares and use the proceeds to finance the transaction.
The Benefit
The deal is a strategic fit given the scope to capitalize on the increasing health-care-driven research and development driven by top-tier research universities. Increasing longevity of the aging U.S. population coupled with biopharma drug development growth opportunities are fueling the institutional life science and medical-market fundamentals. Moreover, long lease terms and top rated, institutional quality tenants assure steady growth in cash flows for Ventas.
Further, addition of 100% private pay assets would increase Ventas’s net operating income (NOI) contribution from private pay assets to 84%, which is encouraging. In fact, pro forma for the Wexford transaction, the assets acquired would reap around 5% of Ventas’s total NOI.
In Conclusion
Ventas’ large and diversified healthcare portfolio will help it benefit from an increasing healthcare spending, aging population and a rise in insured individuals. Further, the above-mentioned acquisition deal is consistent with the company’s strategy of adding high-quality properties generating improving cash flows. Yet, stiff competition keeps us concerned.
Ventas currently has a Zacks Rank #3 (Hold). Investors interested in the REIT industry can also consider stocks like other better-ranked stocks like HCP Inc. (HCP - Free Report) and Omega Healthcare Investors Inc. (OHI - Free Report) . Both the stocks has a Zacks Rank #2 (Buy)..
Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>